This isn't going to hurt at all the right a. If a very lucrative drug making business is not connected to their a lossut ond consumer a division, then that just looks so much. J j has sort of spent the day kind of selling the a the profitability, the prospects of the consumer division. But i think what we all know, what everybody has their eyes on is, you know, what's the future of this farmer company? And i think wat they're trying to do, or at least what the net effect of of this is going to be, to shield it from a lot of liability.
Dr. Ian Lustbader, Clinical Professor of Medicine at NYU Langone, discusses why the shot-or-test rule makes sense. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Health Care Reporter Cynthia Koons explain why Covid pills may save lives, but they won’t end the pandemic. Bloomberg News Health Editor John Lauerman talks about Johnson & Johnson's plan to split off its consumer division, following in the footsteps of other big drugmakers that have moved to focus on the more-profitable pharmaceutical market. Kathy Kraninger, VP of Regulatory Affairs at Solidus Labs, shares her thoughts on crypto manipulation and regulation. And We Drive to the Close with Bill Smead, CIO at Smead Capital Management.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.